Dephosphorylated lysosomal storage disease proteins and methods of use thereof
Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).
1. A conjugate, comprising a p97 polypeptide that is covalently or operatively linked to a recombinant human iduronate-2-sulfatase (IDS) polypeptide that is at least 90% identical to SEQ ID NO:2, where the mannose-6-phosphate (M6P) content of the IDS polypeptide is less than 1.2 pmol M6P/pmol IDS polypeptide and wherein the IDS polypeptide has oligomannose glycans at all 8 of the N-linked glycosylation sites to form a p97 conjugate.
2. A composition, comprising the conjugate of claim 1 , and a pharmaceutically acceptable carrier, where the conjugate is at least 80% pure.
3. The composition of claim 2 , where the human IDS polypeptide is dephosphorylated by enzymatic digestion with an acid phosphatase or an alkaline phosphatase.
4. The composition of claim 3 , where the IDS polypeptide has a M6P content of less than 0.5 pmol M6P/pmol IDS polypeptide, or about 0.15 pmol M6P/pmol IDS polypeptide.
5. The composition of claim 2 , where the human IDS polypeptide is at least 95% identical to SEQ ID NO:2.
6. The composition of claim 5 , where the M6P content is less than 0.5 pmol M6P/pmol IDS polypeptide.
7. The composition of claim 5 , where the M6P content is about or less than 0.15 pmol M6P/pmol IDS polypeptide.